Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANKL-blockade for the treatment of erosive osteoarthritis of interphalangeal finger joints
2015-003223-53Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of denosumab in osteoarthritis (OA), sponsored by Ghent University Hospital. Primary endpoint: Primary: Change in negative evolution of GUSS scores in target interphalangeal joints. Started Sep 2015; status: completed.
02
Drugs
denosumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2015-003223-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003223-53.